Stock ONCY ONCOLYTICS BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Oncolytics Biotech Inc. Nasdaq

Equities

ONCY

CA6823108759

Market Closed - Nasdaq
Other stock markets
 21:00:00 07/06/2024 BST 		5-day change 1st Jan Change
1.05 USD -0.94% Intraday chart for Oncolytics Biotech Inc. -1.87% -22.22%
05-24 Oncolytics Biotech Inc. Presents Two Abstracts At the 2024 American Society of Clinical Oncology Annual Meeting CI
05-24 Oncolytics Biotech Says ASCO Abstracts Highlight Pelareorep's Treatment Potential in Pancreatic Cancer MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oncolytics Biotech Inc. Presents Two Abstracts At the 2024 American Society of Clinical Oncology Annual Meeting
CI
Oncolytics Biotech Says ASCO Abstracts Highlight Pelareorep's Treatment Potential in Pancreatic Cancer
MT
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action
AQ
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
PR
Transcript : Oncolytics Biotech Inc. - Shareholder/Analyst Call
Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Pancreatic Cancer Trial
MT
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
CI
Oncolytics Biotech Brief: Announcing Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
MT
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
PR
Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
CI
RBC on Oncolytics Biotech's Upcoming Type C Meeting With FDA
MT
Oncolytics Biotech Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
AQ
Oncolytics Biotech Reports a First-Quarter Loss of Near $7 Million
MT
Transcript : Oncolytics Biotech Inc., Q1 2024 Earnings Call, May 09, 2024
Oncolytics Biotech Brief: Q1 Basic and diluted loss per common share $0.09
MT
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights
AQ
Oncolytics Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Oncolytics Biotech Receives German Regulatory Clearance to Evaluate Pelareorep with Modified Folfirinox in Pancreatic Cancer
MT
Oncolytics Biotech Brief: Says Received Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
MT
Oncolytics Biotech® Inc. Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX+/- an Anti-PD-L1 Inhibitor in Pancreatic Cancer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ONC Stock
  4. ONCY Stock
  5. News Oncolytics Biotech Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW